

# Global Oncolytic Virus Therapies Market: Focus on Commercialized Therapies, Pipeline Therapies, Type of Virus, Application, Region (15 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030

<https://marketpublishers.com/r/GFA27DD02350EN.html>

Date: April 2021

Pages: 179

Price: US\$ 5,000.00 (Single User License)

ID: GFA27DD02350EN

## Abstracts

Market Report Coverage - Oncolytic Virus Therapies

Market Segmentation

Commercialized Therapies: Imlygic, Oncorine, and RIGVIR

Pipeline Therapies: Phase I, Phase II, Phase III, Phase IV

Type of Virus: Genetically Engineered Oncolytic Viruses (Herpes Simplex Virus, Adenovirus, and Vaccinia Virus), Oncolytic Wild-Type Viruses (Reovirus, Newcastle Disease Virus, and Vesicular Stomatitis Virus)

Application: Solid Tumors (Breast Cancer, Prostate Cancer, Lung Cancer, Glioblastoma, and Melanoma), Hematological Malignancies (Lymphoma, Leukemia, and Myeloma)

Regional Segmentation

North America: U.S.

Europe: Germany, France, Italy, U.K., Latvia, Armenia, Georgia, Rest-of-the-

Europe (Spain, Russia, Switzerland)

Asia-Pacific – Japan, China, Rest-of-APAC (India, Australia, South Korea)

## Growth Drivers

Increasing Incidence of Cancer

Rising Number of Clinical Trials

Increasing Research Funding from National Cancer Institute

Increasing Adoption of Inorganic Growth Strategies in the Market

## Market Challenges

High Cost of Therapy

Lack of Therapy-Specific Assays

## Market Opportunities

Opportunities in the Emerging Economies

Drug Approvals and Strong Pipeline of Oncolytic Virus Therapies

## Key Companies Profiled

Amgen, Inc., DAIICHI SANKYO COMPANY, LIMITED, DNATRIX, Genelux, Oncolytics Biotech, Inc., PsiOxus Therapeutics, RIGVIR Ltd., Shanghai Sunway Biotech Co., Ltd., SillaJen, Inc., Sorrento Therapeutics, Inc., Takara Bio Inc., Transgene sa, VCN Biosciences, ViroCure, Viralytics Ltd.

## Key Questions Answered in this Report:

What are the major market drivers, challenges, and opportunities in the global oncolytic virus therapies market?

What are the key development strategies being implemented by the major players in order to sustain in the competitive market?

What are the key regulatory implications in developed and developing regions for the global oncolytic virus therapies market?

How is each segment of the market expected to grow during the forecast period 2020-2030?

Who are the leading players with significant offerings to the global oncolytic virus therapies market, and what is the expected market dominance for each of these leading players?

What are the adoption trends for oncolytic virus therapies in established economies and emerging economies across the world?

What is the COVID-19 impact on the global oncolytic virus therapies market?

Which companies are anticipated to be highly disruptive in the future, and why?

What are the unmet needs that are yet to be met by the global oncolytic virus therapies with respect to the application areas?

What are the dynamics of various application areas and countries, which are impacting the global oncolytic virus therapies market?

What are the new market opportunities of various technologies that are influencing the growth of the global oncolytic virus therapies market?

How is each segment of the market expected to grow during the forecast period 2020-2030? Following are the segment types:

Commercialized Therapies

Pipeline Therapies

Type of Virus

Application

Region

## Market Overview

Oncolytic virus therapies are overlapping biomedical research fields with similar therapeutic goals, which target DNA or RNA inside or outside the body. These therapies aim at modifying genetic material for the treatment of a disease. Oncolytic virotherapy is a form of gene therapy that used nature's material (virus) to find and destroy malignant cells. Oncolytic virus therapy is "a novel approach to treat, cure, or ultimately prevent disease by changing the expression of a person's genes". Oncolytic virotherapy is a form of gene therapy that used nature's material (virus) to find and destroy malignant cells.

Our healthcare experts have found oncolytic virus therapies to be one of the most rapidly evolving technologies, and the global market is predicted to grow at a CAGR of 26.28% over the forecast period 2020-2030.

Factors fueling the growth of the market include prevalence of cancer, rising number of clinical trials, boosting research funding, and adoption of inorganic growth. Despite rapid advanced industry growth, there are several key issues that need to be addressed to facilitate future growth such as the relatively high total costs of therapies and lacking therapy-specific assay. Further, some of the opportunities such as clinical pipeline of therapies provide growth to the market.

Within the research report, the market has been segmented on the basis of commercialized therapies, pipeline therapies, type of virus, application, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

## Competitive Landscape

The exponential rise in the cases of cancer on the global level has created a buzz among companies to invest in the therapeutics of advanced technologies. Due to a

large number of pipeline therapies and intense market penetration, oncolytic virus therapies have been pioneers in the therapeutic field and have significant competitors in this market.

Based on region, North America held the largest share in 2020, owing to improved healthcare infrastructure, rise in per capita income, and improvised reimbursement policies in the region. Apart from this, Europe and the Asia-Pacific are anticipated to grow at the fastest CAGR during the forecast period.

## Contents

### EXECUTIVE SUMMARY

### 1 PRODUCT DEFINITION

#### 1.1 Inclusion and Exclusion

### 2 MARKET SCOPE

#### 2.1 Scope of Work

#### 2.2 Key Questions Answered in the Report

### 3 RESEARCH METHODOLOGY

#### 3.1 Global Oncolytic Virus Therapies Market: Research Methodology

#### 3.2 Primary Data Sources

#### 3.3 Secondary Data Sources

#### 3.4 Market Estimation Model

#### 3.5 Criteria for Company Profiling

### 4 MARKET OVERVIEW

#### 4.1 Market Definition

#### 4.2 Importance of Oncolytic Virus Therapies in Cancer Treatment

#### 4.3 Market Size and Growth Potential, \$Million, 2019-2030

#### 4.4 COVID-19 Impact on the Global Oncolytic Virus Therapies Market

### 5 INDUSTRY INSIGHTS

#### 5.1 Overview

#### 5.2 Regulatory Scenario

#### 5.3 Legal Requirements and Framework in the U.S

##### 5.3.1 Clinical Trial Authorization

##### 5.3.2 U.S. FDA Guidelines for BLA Submission

#### 5.4 Legal Requirements and Framework in Europe

##### 5.4.1 EMA Biologics License Application Process

##### 5.4.2 Centralized Procedure

##### 5.4.3 Decentralized Procedure

- 5.4.4 Mutual-Recognition Procedure
- 5.5 Legal Requirements and Framework in Asia-Pacific
  - 5.5.1 China
  - 5.5.2 Japan
- 5.6 Expedited Regulatory Designations Around the World
- 5.7 Reimbursement Scenario
- 5.8 Patent Analysis
  - 5.8.1 Patent Filing Trend

## **6 MARKET DYNAMICS**

- 6.1 Overview
- 6.2 Impact Analysis
- 6.3 Market Drivers
  - 6.3.1 Increasing Incidence of Cancer
  - 6.3.2 Rising Number of Clinical Trials
  - 6.3.3 Increasing Research Funding from National Cancer Institute
  - 6.3.4 Increasing Adoption of Inorganic Growth Strategies in the Market
- 6.4 Market Restraints
  - 6.4.1 High Cost of Therapy
  - 6.4.2 Lack of Therapy-Specific Assays
- 6.5 Market Opportunities
  - 6.5.1 Opportunities in the Emerging Economies
  - 6.5.2 Drug Approvals and Strong Pipeline of Oncolytic Virus Therapies

## **7 COMPETITIVE LANDSCAPE**

- 7.1 Synergistic Activities
- 7.2 Business Expansion Activities and Others
- 7.3 Product Launches and Product Updates
- 7.4 Mergers and Acquisitions
- 7.5 Market Share Analysis
- 7.6 Growth Share Analysis
  - 7.6.1 Growth Share Analysis (by Commercialized Therapy)

## **8 ONCOLYTIC VIRUS THERAPIES: EPIDEMIOLOGY ANALYSIS**

## **9 GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET (BY COMMERCIALIZED THERAPIES), \$MILLION, 2019-2030**

- 9.1 Overview
- 9.2 Imlygic
- 9.3 Oncorine
- 9.4 RIGVIR

## **10 GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET (BY PIPELINE THERAPIES), \$MILLION, 2019-2030**

- 10.1 Overview
- 10.2 Phase I
- 10.3 Phase II
- 10.4 Phase III
- 10.5 Phase IV

## **11 GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET (BY TYPE OF VIRUS), \$MILLION, 2019-2030**

- 11.1 Overview
- 11.2 Genetically Engineered Oncolytic Virus
  - 11.2.1 Herpes Simplex Virus (HSV)
  - 11.2.2 Adenovirus
  - 11.2.3 Vaccinia Virus
- 11.3 Oncolytic Wild-Type Virus
  - 11.3.1 Reovirus (Respiratory Enteric Orphan Virus)
  - 11.3.2 Newcastle Disease Virus (NDV)
  - 11.3.3 Vesicular Stomatitis Virus (VSV)

## **12 GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET (BY APPLICATION), \$MILLION, 2019-2030**

- 12.1 Overview
- 12.2 Solid Tumor
  - 12.2.1 Breast Cancer
  - 12.2.2 Prostate Cancer
  - 12.2.3 Lung Cancer
  - 12.2.4 Glioblastoma
  - 12.2.5 Melanoma
  - 12.2.6 Other Applications



## 12.3 Hematological Malignancies

- 12.3.1 Lymphoma
- 12.3.2 Leukemia
- 12.3.3 Myeloma

## **13 GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET (BY REGION), \$MILLION, 2019-2030**

### 13.1 Overview

### 13.2 North America

- 13.2.1 U.S.

### 13.3 Europe

- 13.3.1 U.K.
- 13.3.2 Latvia
- 13.3.3 Georgia
- 13.3.4 Armenia
- 13.3.5 Germany
- 13.3.6 France
- 13.3.7 Italy
- 13.3.8 Rest-of-Europe

### 13.4 Asia-Pacific

- 13.4.1 China
- 13.4.2 Japan
- 13.4.3 Rest-of-APAC

## **14 COMPANY PROFILES**

### 14.1 Overview

### 14.2 Amgen Inc.

- 14.2.1 Company Overview
- 14.2.2 Role of Amgen Inc. in the Global Oncolytic Virus Therapies Market
- 14.2.3 Financials
- 14.2.4 Key Insights about Financial Health of the Company
- 14.2.5 SWOT Analysis

### 14.3 DAIICHI SANKYO COMPANY, LIMITED

- 14.3.1 Company Overview
- 14.3.2 Role of DAIICHI SANKYO COMPANY, LIMITED in the Global Oncolytic Virus Therapies Market
- 14.3.3 Financials

- 14.3.4 Key Insights About Financial Health of the Company
- 14.3.5 SWOT Analysis
- 14.4 DNAtrix
  - 14.4.1 Company Overview
  - 14.4.2 Role of DNAtrix in the Global Oncolytic Virus Therapies Market
  - 14.4.3 SWOT Analysis
- 14.5 Genelux
  - 14.5.1 Company Overview
  - 14.5.2 Role of Genelux in the Global Oncolytic Virus Therapies Market
  - 14.5.3 SWOT Analysis
- 14.6 Oncolytics Biotech, Inc.
  - 14.6.1 Company Overview
  - 14.6.2 Role of Oncolytics Biotech, Inc. in the Global Oncolytic Virus Therapies Market
  - 14.6.3 Financials
  - 14.6.4 SWOT Analysis
- 14.7 PsiOxus Therapeutics
  - 14.7.1 Company Overview
  - 14.7.2 Role of PsiOxus Therapeutics in the Global Oncolytic Virus Therapies Market
  - 14.7.3 SWOT Analysis
- 14.8 RIGVIR Ltd.
  - 14.8.1 Company Overview
  - 14.8.2 Role of RIGVIR Ltd. in the Global Oncolytic Virus Therapies Market
  - 14.8.3 SWOT Analysis
- 14.9 Shanghai Sunway Biotech Co., Ltd.,
  - 14.9.1 Company Overview
  - 14.9.2 Role of Shanghai Sunway Biotech Co., Ltd., in the Global Oncolytic Virus Therapies Market
  - 14.9.3 SWOT Analysis
- 14.1 SillaJen, Inc.
  - 14.10.1 Company Overview
  - 14.10.2 Role of SillaJen, Inc. in the Global Oncolytic Virus Therapies Market
  - 14.10.3 SWOT Analysis
- 14.11 Sorrento Therapeutics, Inc.
  - 14.11.1 Company Overview
  - 14.11.2 Role of Sorrento Therapeutics, Inc. in Global Oncolytic Virus Therapies Market
  - 14.11.3 Financials
  - 14.11.4 Key Insights About Financial Health of the Company
  - 14.11.5 SWOT Analysis
- 14.12 Takara Bio Inc.

- 14.12.1 Company Overview
- 14.12.2 Role of Takara Bio Inc. in the Global Oncolytic Virus Therapies Market
- 14.12.3 Financials
- 14.12.4 Key Insights About Financial Health of the Company
- 14.12.5 SWOT Analysis
- 14.13 Transgene sa
  - 14.13.1 Company Overview
  - 14.13.2 Role of Transgene sa in the Global Oncolytic Virus Therapies Market
  - 14.13.3 Financials
  - 14.13.4 SWOT Analysis
- 14.14 VCNBiosciences
  - 14.14.1 Company Overview
  - 14.14.2 Role of VCNBiosciences in the Global Oncolytic Virus Therapies Market
  - 14.14.3 SWOT Analysis
- 14.15 ViroCure
  - 14.15.1 Company Overview
  - 14.15.2 Role of ViroCure in the Global Oncolytic Virus Therapies Market
  - 14.15.3 SWOT Analysis
- 14.16 Viralytics Ltd. (Merck & Co., Inc.)
  - 14.16.1 Company Overview
  - 14.16.2 Role of Merck & Co., Inc. in the Global Oncolytic Virus Therapies Market
  - 14.16.3 Financials
  - 14.16.4 Key Insights About Financial Health of the Company
  - 14.16.5 SWOT Analysis

## List Of Tables

### LIST OF TABLES

Table 5.1: Regulatory Scenario Across the World

Table 5.2: Expedited Regulatory Designations Around the World

Table 5.3: Key Market Access Landscape (by Country), January 2019

Table 9.1: Commercialized Therapies

Table 10.1: Key Oncolytic Virus Therapies in Clinical Development Phase I, 2020

Table 10.2: Key Oncolytic Virus Therapies in Clinical Development Phase II, 2020

Table 10.3: Key Oncolytic Virus Therapies in Clinical Development Phase III, 2020

Table 11.1: Key Herpes Simplex Virus (HSV)-Based Oncolytic Therapies

Table 11.2: Key Adenovirus-Based Oncolytic Therapies

Table 11.3: Key Vaccinia Virus-Based Oncolytic Therapies

Table 11.4: Key Reovirus-Based Oncolytic Therapies

Table 13.1: Rest-of-APAC - Pipeline Drugs

## List Of Figures

### LIST OF FIGURES

- Figure 1: NCI Fiscal Budget Year on Year, 2013-2018
- Figure 2: Impact Analysis of Market Drivers and Market Challenges on the Global Oncolytic Virus Therapies Market
- Figure 3: Global Oncolytic Virus Therapies Market (by Application), \$Million, 2019 Vs. 2030
- Figure 4: Global Oncolytic Virus Therapies Market (by Type of Virus), \$Million, 2019 vs. 2030
- Figure 5: Global Oncolytic Virus Therapies Market Snapshot, \$Million, 2019 and 2030
- Figure 2.1: Global Oncolytic Virus Therapies Market Segmentation
- Figure 3.1: Global Oncolytic Virus Therapies Market Research Methodology
- Figure 3.2: Primary Research Methodology
- Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
- Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
- Figure 4.1: Global Oncolytic Virus Therapies Market, \$Million, 2019-2030
- Figure 4.2: Global Oncolytic Virus Therapies Market: COVID-19 Impact
- Figure 5.1: Clinical Trial Authorization for Oncolytic Virus Therapies
- Figure 5.2: Steps for Obtaining Marketing Authorization
- Figure 5.3: U.S. FDA Expedited Review Programs
- Figure 5.4: Regulatory Strategy for Oncolytic Virus Therapies in the U.S.
- Figure 5.5: U.S.FDA Review Timeline
- Figure 5.6: Regulatory Strategy for Oncolytic Virus Therapies in Europe
- Figure 5.7: EMA Review Timeline
- Figure 5.9: Overview of PMDA and MLHW Drug Approval Process in Japan
- Figure 5.10: Global Oncolytic Virus Therapies Market: Patent Analysis (by Country and Year), January 2015-March 2021
- Figure 6.1: Impact Analysis
- Figure 6.2: Cancer Cases Projection, 2016-2020
- Figure 6.3: Number of Active and Completed Clinical Trials for Gene Therapy (by Start Date), 2015-2019
- Figure 6.4: SBIR and STTR Grants and Contract Funding, 2008-2018
- Figure 6.5: NCI Fiscal Budget Year-on-Year, 2013-2018
- Figure 6.6: Synergistic Activities, 2018-2020
- Figure 7.1: Share of Key Developments and Strategies, January 2018-March 2021
- Figure 7.2: Synergistic Activities Share (by Company), January 2018-March 2021
- Figure 7.3: Business Expansion Activities Share (by Company), January 2018-March

2021

Figure 7.4: Number of Product Launches (by Company), January 2018-March 2021

Figure 7.5: Mergers and Acquisitions, January 2018-March 2021

Figure 7.6: Market Share Analysis for Global Oncolytic Virus Therapies Market, (by Application), \$Million, 2020

Figure 7.7: Growth Share Analysis for Global Oncolytic Virus Therapies Market (by Commercialized Therapy), 2019-2020

Figure 8.1: Type of Cancer

Figure 8.2: Global Estimated Percent of New Cancer Cases (by Sex), 2030

Figure 8.3: Expected Cancer Cases in the World (by Country), 2030

Figure 8.4: Relative Number of Expected New Cancer Cases (by Country), 2030

Figure 9.1: Global Oncolytic Virus Therapies Market (Imlygic), \$Million, 2019-2030

Figure 9.2: Global Oncolytic Virus Therapies Market (Oncorine), \$Million, 2019-2030

Figure 9.3: Global Oncolytic Virus Therapies Market (RIGVIR), \$Million, 2019-2030

Figure 10.1: Oncolytic Virus Gene Therapy Medicines in Development (by Disease), 2019

Figure 11.1: Global Oncolytic Virus Therapies Market (by Type of Virus), \$Million, 2019-2030

Figure 11.2: Global Oncolytic Virus Therapies Market (by Genetically Engineered Oncolytic Virus), \$Million, 2019 and 2030

Figure 11.3: Global Oncolytic Virus Therapies Market (Herpes Simplex Virus), \$Million, 2019-2030

Figure 11.4: Global Oncolytic Virus Therapies Market (Adenovirus), \$Million, 2019-2030

Figure 11.5: Global Oncolytic Virus Therapies Market (Vaccinia Virus), \$Million, 2019-2030

Figure 11.6: Global Oncolytic Virus Therapies Market (by Oncolytic Wild-Type Virus), \$Million, 2019 and 2030

Figure 11.7: Global Oncolytic Virus Therapies Market (Reovirus), \$Million, 2019-2030

Figure 11.8: Global Oncolytic Virus Therapies Market (Newcastle Disease Virus), \$Million, 2019-2030

Figure 11.9: Global Oncolytic Virus Therapies Market (Vesicular Stomatitis Virus), \$Million, 2019-2030

Figure 12.1: Global Oncolytic Virus Therapies Market (by Application), \$Million, 2019-2030

Figure 12.2: Global Oncolytic Virus Therapies Market (by Solid Tumor), \$Million, 2019 and 2030

Figure 12.3: Global Oncolytic Virus Therapies Market (Breast Cancer), \$Million, 2019-2030

Figure 12.4: Global Oncolytic Virus Therapies Market (Prostate Cancer), \$Million,

2019-2030

Figure 12.5: Global Oncolytic Virus Therapies Market (Lung Cancer), \$Million, 2019-2030

Figure 12.6: Global Oncolytic Virus Therapies Market (Glioblastoma), \$Million, 2019-2030

Figure 12.7: Global Oncolytic Virus Therapies Market (Melanoma), \$Million, 2019-2030

Figure 12.8: Global Oncolytic Virus Therapies Market (Other Applications), \$Million, 2019-2030

Figure 12.9: Global Oncolytic Virus Therapies Market (by Haematological Malignancies), \$Million, 2019 and 2030

Figure 12.10: Global Oncolytic Virus Therapies Market (Lymphoma), \$Million, 2019-2030

Figure 12.11: Global Oncolytic Virus Therapies Market (Leukemia), \$Million, 2019-2030

Figure 12.12: Global Oncolytic Virus Therapies Market (Myeloma), \$Million, 2019-2030

Figure 13.1: Global Oncolytic Virus Therapies Market (by Region), 2019-2030

Figure 13.2: Global Oncolytic Virus Therapies Market (by Region), \$Million, 2019-2030

Figure 13.3: Global Oncolytic Virus Therapies Market Share (by Region), \$Million, 2019

Figure 13.4: Global Oncolytic Virus Therapies Market Share (by Region), \$Million, 2030

Figure 13.5: North America Oncolytic Virus Therapies Market, \$Million, 2019-2030

Figure 13.6: North America: Market Dynamics

Figure 13.7: U.S. Oncolytic Virus Therapies Market, \$Million, 2019-2030

Figure 13.8: Europe Oncolytic Virus Therapies Market, \$Million, 2019-2030

Figure 13.9: Europe: Market Dynamics

Figure 13.10: Europe Oncolytic Virus Therapies Market (by Country), \$Million, 2019-2030

Figure 13.11: U.K. Oncolytic Virus Therapies Market, \$Million, 2019-2030

Figure 13.12: Latvia Oncolytic Virus Therapies Market, \$Million, 2019-2030

Figure 13.13: Georgia Oncolytic Virus Therapies Market, \$Million, 2019-2030

Figure 13.14: Armenia Oncolytic Virus Therapies Market, \$Million, 2019-2030

Figure 13.15: Germany Oncolytic Virus Therapies Market, \$Million, 2019-2030

Figure 13.16: France Oncolytic Virus Therapies Market, \$Million, 2019-2030

Figure 13.17: Italy Oncolytic Virus Therapies Market, \$Million, 2019-2030

Figure 13.18: Rest-of-Europe Oncolytic Virus Therapies Market, \$Million, 2019-2030

Figure 13.19: Asia-Pacific Oncolytic Virus Therapies Market, \$Million, 2019-2030

Figure 13.20: APAC: Market Dynamics

Figure 13.21: APAC Oncolytic Virus Therapies Market (by Country), \$Million, 2019-2030

Figure 13.22: China Oncolytic Virus Therapies Market, \$Million, 2019-2030

Figure 13.23: Japan Oncolytic Virus Therapies Market, \$Million, 2019-2030

Figure 13.24: RoAPAC Oncolytic Virus Therapies Market, \$Million, 2019-2030

- Figure 14.1: Total Number of Companies Profiled
- Figure 14.2: Amgen Inc.: Product Portfolio
- Figure 14.3: Amgen Inc.: Overall Financials, \$Million, 2018-2020
- Figure 14.4: Amgen Inc.: Revenue (by Region), \$Million, 2018-2020
- Figure 14.5: Amgen Inc. R&D Expenditure, \$Billion, 2018-2020
- Figure 14.6: Amgen Inc.: SWOT Analysis
- Figure 14.7: DAIICHI SANKYO COMPANY, LIMITED: Product Portfolio
- Figure 14.8: DAIICHI SANKYO COMPANY, LIMITED: Overall Financials, \$Billion, 2017-2019
- Figure 14.9: Amgen Inc. R&D Expenditure, \$Billion, 2017-2019
- Figure 14.10: DAIICHI SANKYO COMPANY, LIMITED: SWOT Analysis
- Figure 14.11: DNAtrix: Product Portfolio
- Figure 14.12: DNAtrix: SWOT Analysis
- Figure 14.13: Genelux: Product Portfolio
- Figure 14.14: Genelux: SWOT Analysis
- Figure 14.15: Oncolytics Biotech, Inc.: Product Portfolio
- Figure 14.16: Oncolytics Biotech, Inc.: SWOT Analysis
- Figure 14.17: PsiOxus Therapeutics: Pipeline Product Portfolio
- Figure 14.18: PsiOxus Therapeutics: SWOT Analysis
- Figure 14.19: RIGVIR Ltd.: Overall Service Portfolio
- Figure 14.20: RIGVIR Ltd.: SWOT Analysis
- Figure 14.21: Product Portfolio: Shanghai Sunway Biotech Co., Ltd.,
- Figure 14.22: Shanghai Sunway Biotech Co., Ltd.: SWOT Analysis
- Figure 14.23: SillaJen, Inc.: Product Portfolio
- Figure 14.24: SillaJen, Inc.: SWOT Analysis
- Figure 14.25: Sorrento Therapeutics, Inc.: Product Portfolio
- Figure 14.26: Sorrento Therapeutics, Inc.: Overall Financials, 2017-2019
- Figure 14.27: Sorrento Therapeutics, Inc. R&D Expenditure, \$Million, 2017-2019
- Figure 14.28: Sorrento Therapeutics, Inc.: SWOT Analysis
- Figure 14.29: Takara Bio Inc.: Product Portfolio
- Figure 14.30: Takara Bio Inc.: Overall Financials, 2017-2019
- Figure 14.31: Takara Bio Inc.: Revenue (by Segment), \$Million, 2017-2019
- Figure 14.32: Takara Bio Inc.: Revenue (by Region), \$Million, 2017-2019
- Figure 14.33: Takara Bio Inc.: R&D Expenditure, 2017-2019
- Figure 14.34: Takara Bio Inc.: SWOT Analysis
- Figure 14.35: Transgene sa: Product Portfolio
- Figure 14.36: Transgene sa: Overall Financials, \$Million, 2017-2019
- Figure 14.37: Transgene sa: SWOT Analysis
- Figure 14.38: VCNBiosciences: Pipeline Product Portfolio



Figure 14.39: VCNBiosciences: SWOT Analysis

Figure 14.40: ViroCure: Product Portfolio

Figure 14.41: ViroCure: SWOT Analysis

Figure 14.42: Viralytics Ltd., (Merck & Co., Inc.): Product Portfolio

Figure 14.43: Merck & Co., Inc.: Overall Financials, \$Million, 2018-2020

Figure 14.44: Merck & Co., Inc.: Revenue (by Segment), \$Million, 2018-2020

Figure 14.45: Merck & Co., Inc.: Revenue (by Region), \$Million, 2018-2020

Figure 14.46: Merck & Co., Inc.: R&D Expenditure, \$Million, 2018-2020

Figure 14.47: Merck & Co., Inc.: SWOT Analysis

## I would like to order

Product name: Global Oncolytic Virus Therapies Market: Focus on Commercialized Therapies, Pipeline Therapies, Type of Virus, Application, Region (15 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030

Product link: <https://marketpublishers.com/r/GFA27DD02350EN.html>

Price: US\$ 5,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GFA27DD02350EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970